Chloroquine-d5 (phosphate)
(Synonyms: 磷酸氯喹 d5 (二磷酸盐)) 目录号 : GC45885An internal standard for the quantification of chloroquine
Cas No.:1854126-42-3
Sample solution is provided at 25 µL, 10mM.
Chloroquine-d5 is intended for use as an internal standard for the quantification of chloroquine by GC- or LC-MS. Chloroquine is an aminoquinoline that is an inhibitor of autophagy and has antimalarial and anticancer activities.1,2,3 Chloroquine inhibits autophagosome-lysosome fusion in HeLa cells when used at a concentration of 100 μM.1 It is active against the chloroquine-sensitive GC03 strain of P. falciparum (IC50 = 29.2 nM) but has decreased activity against mutant pfcrt P. falciparum (IC50s = 100-150 nM).2 Chloroquine inhibits the growth of human SSC25 and CAL27 oral squamous cell carcinoma cells (IC50s = 29.9 and 17.3 μM, respectively), as well as A498, SN12C, RXF393, and 769-P renal cancer cells (IC50s = 16, 62, 81, and 25 μM, respectively).3,4 It reduces tumor growth in a CAL27 mouse xenograft model and a 4T1 mouse allograft model when administered at a dose of 50 mg/kg.3,5
|1. Mauthe, M., Orhon, I., Rocchi, C., et al. Chloroquine inhibits autophagic flux by decreasing autophagosome-lysosome fusion. Autophagy 14(8), 1435-1455 (2018).|2. Sidhu, A.B.S., Verdier-Pinard, D., and Fidock, D.A. Chloroquine resistance in Plasmodium falciparum malaria parasites conferred by pfcrt mutations. Science 298(5591), 210-213 (2002).|3. Jia, L., Wang, J., Wu, T., et al. In vitro and in vivo antitumor effects of chloroquine on oral squamous cell carcinoma. Mol. Med. Rep. 16(5), 5779-5786 (2017).|4. Grimaldi, A., Santini, D., Zappavigna, S., et al. Antagonistic effects of chloroquine on autophagy occurrence potentiate the anticancer effects of everolimus on renal cancer cells. Cancer Biol. Ther. 16(4), 567-579 (2015).|5. Jiang, P.-D., Zhao, Y.-L., Deng, X.-Q., et al. Antitumor and antimetastatic activities of chloroquine diphosphate in a murine model of breast cancer. Biomed. Pharmacother. 64(9), 609-614 (2010).
Cas No. | 1854126-42-3 | SDF | |
别名 | 磷酸氯喹 d5 (二磷酸盐) | ||
Canonical SMILES | ClC1=CC=C2C(N=CC=C2NC(C)CCCN(CC)C([2H])([2H])C([2H])([2H])[2H])=C1.O=P(OO)=O.O=P(OO)=O.[HH].[HH] | ||
分子式 | C18H21ClD5N3.2H3O4P | 分子量 | 520.9 |
溶解度 | PBS (pH 7.2): 10 mg/ml | 储存条件 | Store at -20°C |
General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。 为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。 |
||
Shipping Condition | 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。 |
制备储备液 | |||
1 mg | 5 mg | 10 mg | |
1 mM | 1.9198 mL | 9.5988 mL | 19.1975 mL |
5 mM | 0.384 mL | 1.9198 mL | 3.8395 mL |
10 mM | 0.192 mL | 0.9599 mL | 1.9198 mL |
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
% DMSO % % Tween 80 % saline | ||||||||||
计算重置 |
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >99.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet